Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By Soverini Simona   De Benedittis Caterina   Papayannidis Cristina   Paolini Stefania   Venturi Claudia   Iacobucci Ilaria   Luppi Mario   Bresciani Paola   Salvucci Marzia   Russo Domenico   Sica Simona   Orlandi Ester   Intermesoli Tamara   Gozzini Antonella   Bonifacio Massimiliano   Rigolin Gian Matteo   Pane Fabrizio   Baccarani Michele   Cavo Michele   Martinelli Giovanni  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

Blackwell Publishing

Access to resources Recommend Favorite

Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation

By Matz Mareen   Naik Marcel   Mashreghi Mir-Farzin   Glander Petra   Neumayer Hans-H   Budde Klemens  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 1, 2011-01 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite

Does the small tyrosine kinase inhibitor imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?

By Welsh Nils  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 11, 2012-11 ,pp. : 1743-1750

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetic differences and drug–drug interactions in immunosuppressive therapy

By Warrington Jill S   Shaw Leslie M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 3, 2005-10 ,pp. : 487-503

Informa Healthcare

Access to resources Recommend Favorite

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

By Vries Nienke  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 443-449

Springer Publishing Company

Access to resources Recommend Favorite